Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-28T00:32:10.603Z Has data issue: false hasContentIssue false
  • English
  • Français

Quality of life assessment in patients with moderate to severe allergic rhinitis treated with montelukast and/or intranasal steroids: a randomised, double-blind, placebo-controlled study

Published online by Cambridge University Press:  11 March 2014

B-S Goh ,
M I M Ismail  and
S Husain
B-S Goh*
Affiliation:
Department of Otorhinolaryngology Head and Neck Surgery, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, Kuala Lumpur, Malaysia Institute of Ear, Hearing and Speech, Universiti Kebangsaan Malaysia, Kuala Lumpur, Malaysia
M I M Ismail
Affiliation:
Department of Otorhinolaryngology, Hospital Melaka, Malacca, Malaysia
S Husain
Affiliation:
Department of Otorhinolaryngology Head and Neck Surgery, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latif, Bandar Tun Razak, Kuala Lumpur, Malaysia
*
Address for correspondence: Associate Prof B-S Goh, Department of Otorhinolaryngology Head and Neck Surgery, Universiti Kebangsaan Malaysia Medical Centre, Jalan Yaacob Latiff, Bandar Tun Razak, 56000 Kuala Lumpur, Malaysia Fax: +60 3 914 56675 E-mail: [email protected]
Get access Rights & Permissions [Opens in a new window]

Abstract

Objective:

This study investigated improvements in quality of life associated with eight weeks of montelukast and/or intranasal steroid treatment for moderate to severe allergic rhinitis.

Methods:

A single-centre, prospective, randomised, double-blind, placebo-controlled study was carried out. Assessments were made using the Rhinoconjunctivitis Quality of Life Questionnaire and symptom scales.

Results:

A total of 128 patients (aged 13–51 years) were randomly assigned to one of two groups. In the montelukast group, patients were treated with montelukast tablets and fluticasone propionate nasal spray (n = 64). In the placebo group, treatment comprised a placebo and fluticasone propionate. The results showed significant improvements in symptom scores and quality of life scores for both groups after one month and two months of treatment, compared with baseline values; these improvements were significantly greater for the montelukast group compared with the placebo group. The mean number of loratadine tablets taken by each patient during the study period was only 0.73 for the montelukast group compared with 9 for the placebo group.

Conclusion:

The combination of montelukast tablets and fluticasone propionate nasal spray improved symptom control and overall quality of life for moderate to severe allergic rhinitis patients.

Keywords

Allergic RhinitisQuality Of LifeMontelukastFluticasone Propionate
Type
Main Articles
Information
The Journal of Laryngology & Otology , Volume 128 , Issue 3 , March 2014 , pp. 242 - 248
Copyright
Copyright © JLO (1984) Limited 2014 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1Bousquet, J, van Cauwenberge, P, Khaltaev, N; Aria Workshop Group, World Health Organization. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol 2001;108:S147–334CrossRefGoogle ScholarPubMed
2Linneberg, A, Nielsen, NH, Madsen, F, Frølund, L, Dirksen, A, Jørgensen, T. Increasing prevalence of specific IgE to aeroallergens in an adult population: two cross-sectional surveys 8 years apart: the Copenhagen Allergy Study. J Allergy Clin Immunol 2000;106:247–52CrossRefGoogle Scholar
3Blaiss, MS. Cognitive, social, and economic costs of allergic rhinitis. Allergy Asthma Proc 2000;21:7–13CrossRefGoogle ScholarPubMed
4Crystal-Peters, J, Crown, WH, Goetzel, RZ, Schutt, DC. The cost of productivity losses associated with allergic rhinitis. Am J Manag Care 2000;6:373–8Google ScholarPubMed
5Kremer, B, den Hartog, HM, Jolles, J. Relationship between allergic rhinitis, disturbed cognitive function and psychological well-being. Clin Exp Allergy 2002;32:1310–15CrossRefGoogle ScholarPubMed
6Bousquet, J, van Cauwenberge, P, Khaltaev, N and the workshop expert panel. Allergic rhinitis and its impact on astma (ARIA), in collaboration with the World Health Organization. Executive summary of the workshop report. Allergy 2002;57:841–55CrossRefGoogle Scholar
7Okuda, M, Watase, T, Mezawa, A, Liu, CM. The role of leukotriene D4 in allergic rhinitis. Ann Allergy 1988;60:537–40Google ScholarPubMed
8Storms, W, Michel, TM, Knorr, B, Noonan, G, Shapiro, G, Zhang, J et al. Clinical safety and tolerability of montelukast, a leukotriene receptor antagonist, in controlled clinical trials in patients aged > or = 6 years. Clin Exp Allergy 2001;31:77–87Google Scholar
9Nayak, AS, Philip, G, Lu, S, Malice, MP, Reiss, TF. Efficacy and tolerability of montelukast alone or in combination with loratadine in seasonal allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial performed in the fall. Ann Allergy Asthma Immunol 2002;88:592–600CrossRefGoogle ScholarPubMed
10Van Adelsberg, J, Philip, G, LaForce, CF, Weinstein, SF, Menten, J, Malice, MP et al. Randomized controlled trial evaluating the clinical benefit of montelukast for treating spring seasonal allergic rhinitis. Ann Allergy Asthma Immunol 2003;90:214–22CrossRefGoogle ScholarPubMed
11Patel, P, Philip, G, Yang, W, Call, R, Horak, F, LaForce, C et al. Randomized, double-blind, placebo-controlled study of montelukast for treating perennial allergic rhinitis. Ann Allergy Asthma Immunol 2005;95:551–7CrossRefGoogle ScholarPubMed
12Juniper, EF, Thompson, AK, Ferrie, PJ, Roberts, JN. Development and validation of the mini Rhinoconjunctivitis Quality of Life Questionnaire. Clin Exp Allergy 2000;30:132–40CrossRefGoogle ScholarPubMed
13Virchow, JC, Bachert, C. Efficacy and safety of montelukast in adults with asthma and allergic rhinitis. Respir Med 2006;100:1952–9CrossRefGoogle ScholarPubMed